Navigation Links
Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
Date:8/8/2008

EAST SETAUKET, N.Y., Aug. 8 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today that lead compounds from each of two different types of drugs being developed as potential treatment for specific types of brain cancers have activity against human pancreatic cancers in a mouse model.

Dr. John S. Kovach, President and CEO of Lixte, said, "Lixte previously reported that lead compounds from each of two different classes of pharmacologic agents have significant inhibitory activity against several types of human cancers in the test tube and against brain cancers in animal models. We have now found that two different lead compounds also have statistically significant activity against human pancreatic cancer cells growing in mice. These are early studies and there is no evidence that these drugs are able to eliminate pancreatic cancers but rather slow their growth. We are encouraged, however, that two classes of our drugs have activity against this devastating cancer in addition to glioblastoma multiforme, the most common and most malignant form of brain cancer."

About Lixte Biotechnology Holdings, Inc.:

Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers.

Forward-Looking Statements:

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
2. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
3. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
4. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
6. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
7. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2008)...ewswire-FirstCall/ --,Pharmaceutical company Pharm... the Phase 3 clinical trial evaluating the long te...tasis has concluded with no serious,adverse events...atment., A total of 123 subjects started treatmen...ects completed the full 12 months of the trial. Of...
(Date:8/19/2008)...- Particle Sciences Inc. has,expanded its Combinat...d,pilot production capabilities with the installat...ing line. The core of the pilot line,comprising a...20T injection,molder, enables the production of hi...ition gives Particle Sciences the ability to go fr...
(Date:8/19/2008)...used to identify molecular,signature of motor neur...-USNewswire/ -- ALS Therapy,Development Institute ...LS,biomarker effort using blood samples collected ...ps. These ongoing projects are part of the,Institu...ression of genes,and proteins, at the onset of, an...
(Date:8/19/2008)...ll/ -- Vical Incorporated,(Nasdaq: VICL ) today a...ska,Institute, a leading European medical universi...se Control (SMI), a governmental expert agency, to...iojector(R) 2000,needle-free injection system (Bio...multivalent preventive DNA vaccine against HIV., ...
Breaking Medicine Technology:12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 212 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 3Particle Sciences Expands Its Combination Product Capabilities 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 2Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 4Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 5Many States Still Fall Short in Emergency Preparedness 3A Report 8484 1Many States Still Fall Short in Emergency Preparedness 3A Report 8484 2Many States Still Fall Short in Emergency Preparedness 3A Report 8484 3Many States Still Fall Short in Emergency Preparedness 3A Report 8484 4Rhode Island Hospital to study driving ability of cognitively impaired elders 8483 1NightHawk Radiology Holdings Inc to Speak at Annual JPMorgan Healthcare Conference on January 10 2008 8481 1NightHawk Radiology Holdings Inc to Speak at Annual JPMorgan Healthcare Conference on January 10 2008 8481 2SecureWorks Designated as a Qualified Security Assessor for PCI Audits 8478 1SecureWorks Designated as a Qualified Security Assessor for PCI Audits 8478 2
...ce shortly, CARMIEL, Israel, April 18, 2007 /PRNew.... today announced that it has received,written not...ation,(FDA) that it may initiate a Phase III clini... candidate, prGCD, a proprietary plant,cell expres...GCD),for the treatment of Gaucher Disease, a lyso...
... out of ten patients taking,once-daily Lialda rema...TON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- ...nsion study (303),presented at the British Society...tland in March 2007 showed Shire plc,s,Lialda(mesa...atients. Today, secondary endpoints of study 303 w...
Other Medicine Technology:Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD 2Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
... of Missouri birth statistics by researchers at Wa...s appearing// in the February issue of the America... African-American women are three times more likel...rematurely than Caucasian women. In addition, th...
..., a clinical assistant professor in Indiana Univer...ience//, has offered some tips to help parents of ...enage children. Teenage is the most difficult pha...and romance form an integral part of this mind-bog...
...ancer-fighting film that could be applied directly... can be made into any size and shape, is capable o... site as it dissolves over several weeks. This eff...bypass administering conventional chemotherapy tre...
...succumbed to the flu, in British Columbia//. The...ly peaks in the months of December and January. Th...ters, say experts. According to Dr. Theresa Tam o...gency of Canada, in an average year, about 4,000 C...
Other Medicine News:Health News:African-American Mothers More Likely to Deliver Prematurely 2Health News:A Better Way to Deliver Cancer Drugs 2Health News:Flu Strikes Late - Child Succumbs 2
...e (GH) is a monomeric protein produced and stored ...H is released from the pituitary into the bloodstr...trol of hypothalamic somatostatin (SS) and GH-rele...of GH release appears to be regulated by somatosta...
...he most potent glucocorticoid produced by the huma...d with high affinity to corticosteroid-binding glo...lbumin. Cortisol acts on specific intracellular re...ms, including immune function, glucose counter-reg...
...growth factor I (IGF-I or somatomedin C) is a 7.6 ...ts as a potent mitogen of cellular proliferation, ...urface receptors. In the circulation, IGF-I is bou...to regulate the actions of IGF-I by modulating the...
...growth factor I (IGF-I or somatomedin C) is a 7.6 ...ts as a potent mitogen of cellular proliferation, ...urface receptors. In the circulation, IGF-I is bou...to regulate the actions of IGF-I by modulating the...
Medicine Products: